Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations

Bibliography

• Alzheimer’s Association. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement 2012;8(2):131-68
   PubMed Web of Science ®Google Scholar
• Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010;19(R1):R4-11
   PubMedGoogle Scholar
• Fleming L. Recombinant uncertainty in technological search. Manage Sci 2001;47(1):117-32
   Web of Science ®Google Scholar
• Jaffe AB, Trajtenberg M. International knowledge flows: evidence from patent citations. Econ Innov New Technol 1999;8(1-2):105-36
   Google Scholar
• Érdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the U.S. patent citation network. Scientometrics 2013;95(1):225-42
   Web of Science ®Google Scholar
• Stolpe M. Determinants of knowledge diffusion as evidenced in patent data: the case of liquid crystal display technology. Res Policy 2002;31(7):1181-98
   Web of Science ®Google Scholar
• Narin F. Patent bibliometrics. Scientometrics 1994;30(1):147-55
   Web of Science ®Google Scholar
• Karki M. Patent citation analysis: a policy analysis tool. World Pat Inf 1997;19(4):269-72
   Google Scholar
• Chang SB, Lai KK, Chang SM. Exploring technology diffusion and classification of business methods: using the patent citation network. Technol Forecast Soc 2009;76(1):107-17
   Web of Science ®Google Scholar
• Griliches Z. Patent statistics as economic indicators: a survey. J Econ Lit 1990;28(4):1661-707
   Web of Science ®Google Scholar
• Sorenson O, Rivkin JW, Fleming L. Complexity, networks and knowledge flow. Res Policy 2006;35(7):994-1017
   Web of Science ®Google Scholar
• Choe H, Lee DH, Seo IW, et al. Patent citation network analysis for the domain of organic photovoltaic cells: country, institution, and technology field. Renew Sust Energ Rev 2013;26:492-505
   Google Scholar
• Cho TS, Shih HY. Patent citation network analysis of core and emerging technologies in Taiwan: 1997–2008. Scientometrics 2011;89(3):795-811
   Web of Science ®Google Scholar
• Li X, Chen H, Huang Z, et al. Patent citation network in nanotechnology (1976–2004). J Nanopart Res 2007;9(3):337-52
   Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar
• Lukiw WJ. Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert Opin Emerg Drugs 2012;17(1):43-60
   Web of Science ®Google Scholar
• Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7(3):167-85
   PubMed Web of Science ®Google Scholar
• Misra S, Medh B. Drug development status for Alzheimer’s disease: present scenario. Neurol Sci 2013;34(6):831-9
   PubMed Web of Science ®Google Scholar
• Lioyd M, Mokdsi G, Spielthenner D. Clearing the fog: patenting trends for the treatment of Alzheimer’s disease. Pharm Pat Anal 2012;1(4):437-55
   PubMedGoogle Scholar
• Hu YJ, Scherngell T, Man SN, et al. Is the United States still dominant in the global pharmaceutical innovation network? PLoS One 2013;8(11):e77247
   PubMedGoogle Scholar
• Boccaletti S, Latora V, Moreno Y, et al. Complex networks: structure and dynamics. Phys Rep 2006;424(4–5):175-308
   Web of Science ®Google Scholar
• Caldwell WS, Lippiello PM; inventors. R. J. Reynolds Tabacco Company, USA. Assignee Method for treatment of neurodegenerative diseases. US5212188; 1993
   Google Scholar
• Gold M, Alderton C, Zvartau-Hind M, et al. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer’s disease. Alzheimers Dement 2009;5(4):P86
   Google Scholar
• Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-51
   PubMed Web of Science ®Google Scholar
• Geels FW. Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a case-study. Res Policy 2002;31(8-9):1257-74
   Web of Science ®Google Scholar
• Harhoff D, Narin F, Scherer FM, et al. Citation frequency and the value of patented inventions. Rev Econ Stat 1999;81(3):511-15
   Web of Science ®Google Scholar
• Harhoff D, Scherer FM, Vopel K. Citations, family size, opposition and the value of patent rights. Res Policy 2003;32(8):1343-63
   Web of Science ®Google Scholar
• Trajtenberg M. A penny for your quotes: patent citations and the value of innovations. Rand J Econ 1990;21(1):172-87
   Web of Science ®Google Scholar
• Rosini M, Simoni E, Bartolini M, et al. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 2008;51(15):4381-4
   PubMed Web of Science ®Google Scholar
• Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer’s disease. J Med Chem 2012;55(22):9708-21
   PubMed Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51(3):347-72
   PubMed Web of Science ®Google Scholar
• Chen X, Zenger K, Lupp A, et al. Tacrine-silibinin codrug shows neuro- and hepato protective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. J Med Chem 2012;55(11):5231-42
   PubMed Web of Science ®Google Scholar
• Luo Z, Sheng J, Sun Y, et al. Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen. J Med Chem 2013;56(22):9089-99
   PubMed Web of Science ®Google Scholar
• Belluti F, Rampa A, Gobbi S, et al. Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimer’s disease: a patent review (2010-2012). Expert Opin Ther Pat 2013;23(5):581-96
   PubMed Web of Science ®Google Scholar
• Chen YS, Chang KC. Using neural network to analyze the influence of the patent performance upon the market value of the US pharmaceutical companies. Scientometrics 2009;80(3):637-55
   Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-90
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu Y, Zheng M, et al. Patent indicators: a window to pharmaceutical market success. Expert Opin Ther Pat 2013;23(7):765-71
   PubMed Web of Science ®Google Scholar